Integrating new treatment options into the management of adult ITP

James Granfortuna
University of North Carolina Medical Center at Chapel Hill, USA

Treatment of Steroid resistant ITP in adults can be challenging in patients who are actively bleeding. The majority of novel therapies that have been developed in the last few years including anti CD 20 monoclonal antibody therapy (Rituximab) and thrombopoietic growth factors, romiplostim and eltombopag, take time to work. Combinations of active agents may accelerate the response rate. Splenectomy and the use of immunosuppressive agents may still have an important role in the acute management. A case of resistant ITP will be discussed in the context of currently available treatment modalities.

Biography
James Granfortuna MD FACP graduated from Mount Sinai School of Medicine in 1980 and completed a Hematology Oncology Fellowship at the State University of NY Health Sciences Center in Syracuse NY in 1987. He is board certified in both specialties. He is currently an Associate Professor of Clinical Medicine at the Cone Health Internal Medicine Teaching Program in Greensboro, NC.

james.granfortuna@conehealth.com

Notes: